Amyloid-β interacts with blood-brain barrier function in dementia: A systematic review

Journal of Alzheimer's Disease

Volumn 35, Issue 4, 2013, Pages 859-873

  Burgmans, Saartje ^a   Van De Haar, Harm J ^a   Verhey, Frans R J ^a   Backes, Walter H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; amyloid ; blood brain barrier; dementia; vascular dementia

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CLEARANCE; DEMENTIA; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACEREBRAL DRUG ADMINISTRATION; MICROANGIOPATHY; MICROVASCULAR ENDOTHELIAL CELL; MULTIINFARCT DEMENTIA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SYSTEMATIC REVIEW;

EID: 84878887419     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122155     Document Type: Review

References (104)

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
2. Echavarri C, Burgmans S, Caballero MC, Garcia-Bragado F, Verhey FR, Uylings HB (2012) Co-occurrence of different pathologies in dementia: Implications for dementia diagnosis. J Alzheimers Dis 30, 909-917.
3. Kalaria RN (2010) Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. Nutr Rev 68, S74-S87.
4. Farrall AJ,Wardlaw JM(2009) Blood-brain barrier: Ageing and microvascular disease-systematic review and metaanalysis. Neurobiol Aging 30, 337-352.
5. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG (2011) Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 82, 126-135.
6. Wardlaw JM (2010) Blood-brain barrier and cerebral small vessel disease. J Neurol Sci 299, 66-71.
7. Anderson VC, Lenar DP, Quinn JF, Rooney WD (2011) The blood-brain barrier and microvascular water exchange in alzheimer's disease. Cardiovasc Psychiatry Neurol 2011, 615829.
8. Masters CL, Simms G,WeinmanNA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
9. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
10. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 110, 1129-1134.
11. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120, 287-296.
12. Donahue JE, Johanson CE (2008) Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 67, 261-270.
13. Pahnke J, Walker LC, Scheffler K, Krohn M (2009) Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev 33, 1099-1108.
14. Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, Bogdanovic N (2009) Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 283, 99-106.
15. Lee ST, Chu K, Jung KH, Jeon D, Bahn JJ, Kim JH, Lee SK, Kim M, Roh JK (2010) Dysfunctional characteristics of circulating angiogenic cells in Alzheimer's disease. J Alzheimers Dis 19, 1231-1240.
16. Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K, Yoshita M, Yamada M (2007) Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord 23, 241-245.
17. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Muller M, Scheltens P, Lammertsma AA, van Berckel BN (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181-189.
18. Hartz AMS, Bauer B, Soldner ELB, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Kluenemann HH, Schuierer G, Schlachetzki F (2012) Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514-523.
19. Jeynes B, Provias J (2009) Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neurosci Lett 463, 244-248.
20. Jeynes B, Provias J (2011) An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis. Neurosci Lett 487, 389-393.
21. Jeynes B, Provias J (2008) Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 5, 432-437.
22. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 6, e23789.
23. Wilcock DM, Vitek MP, Colton CA (2009) Vascular amyloid alters astrocyticwater and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience 159, 1055-1069.
24. Clifford PM, Siu G, Kosciuk M, Levin EC, Venkataraman V, D'Andrea MR, Nagele RG (2008) alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy. Brain Res 1234, 158-171.
25. Kawai M, Cras P, Perry G (1992) Serial reconstruction of beta-protein amyloid plaques-relationship to microvessels and size distribution. Brain Res 592, 278-282.
26. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG (2008) Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 1230, 273-280.
27. Vinters HV, Secor DL, Read SL, Frazee JG, Tomiyasu U, Stanley TM, Ferreiro JA, Akers MA (1994) Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: An immunohistochemical and ultrastructural study. Ultrastruct Pathol 18, 333-348.
28. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, Tavares R, Yang WT, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112, 405-415.
29. Carrano A, Hoozemans JJ, van derVies SM, Rozemuller AJ, van Horssen J, de Vries HE (2011) Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15, 1167-1178.
30. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu GJ, Banks WA, Butterfield DA (2010) Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease Implications for A beta accumulation in AD brain. Free Radic Biol Med 49, 1798-1803.
31. Wilhelmus MM, Otte-Holler I, van Triel JJ, Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM(2007) Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989-1999.
32. Banks WA, Kastin AJ, Barrera CM, Maness LM (1991) Lack of saturable transport across the blood-brain barrier in either direction for beta-amyloid1-28 (Alzheimer's disease protein). Brain Res Bull 27, 819-823.
33. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S, Nagele RG (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223-236.
34. Jancso G, Domoki F, Santha P, Varga J, Fischer J, Orosz K, Penke B, Becskei A, Dux M, Toth L (1998) beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 253, 139-141.
35. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF (2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313, 1370-1378.
36. Pluta R, Barcikowska M, Januszewski S, Misicka A, Lipkowski AW (1996) Evidence of blood-brain barrier permeability/leakage for circulating human Alzheimer's beta-amyloid-(1-42)-peptide. Neuroreport 7, 1261-1265.
37. Rhodin JA, Thomas TN, Clark L, Garces A, Bryant M(2003) In vivo cerebrovascular actions of amyloid beta-peptides and the protective effect of conjugated estrogens. J Alzheimers Dis 5, 275-286.
38. Ryu JK, McLarnon JG (2008) Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 29, 254-266.
39. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier. J Clin Investig 106, 1489-1499.
40. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M (1999) Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 818, 105-117.
41. Jablonski M, Maciejewski R, Januszewski S, Ulamek M, Pluta R (2011) One year follow up in ischemic brain injury and the role of Alzheimer factors. Physiol Res 60(Suppl 1), S113-S119.
42. Pluta R, Januszewski S, Ulamek M (2008) Ischemic blood-brain barrier and amyloid in white matter as etiological factors in leukoaraiosis. Acta Neurochir Suppl 102, 353-356.
43. Baiguera S, Fioravanzo L, Grandi C, Di Liddo R, Parnigotto PP, Folin M (2009) Involvement of the receptor for advanced glycation-end products (RAGE) in beta-amyloidinduced toxic effects in rat cerebromicrovascular endothelial cells cultured in vitro. Int J Mol Med 24, 9-15.
44. Balcells M, Wallins JS, Edelman ER (2008) Amyloid beta toxicity dependent upon endothelial cell state. Neurosci Lett 441, 319-322.
45. Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP (1997) Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 68, 1870-1881.
46. Cantara S, Thorpe PE, Ziche M, Donnini S (2007) TAT-BH4 counteracts A beta toxicity on capillary endothelium. FEBS Lett 581, 702-706.
47. Davies TA, Billingslea AM, Long HJ, Tibbles H,Wells JM, Eisenhauer PB, Smith SJ, Cribbs DH, Fine RE, Simons ER (1998) Brain endothelial cell enzymes cleave plateletretained amyloid precursor protein. J Lab Clin Med 132, 341-350.
48. Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P (2007) Comparative effects of A beta((1-42))-Al complex from rat and human amyloid on rat endothelial cell cultures. J Alzheimers Dis 11, 33-44.
49. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE (2000) Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: Increased toxicity of Dutch-type mutant. J Neurosci Res 60, 804-810.
50. Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, Zlokovic BV, Kalra VK (2002) Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol Cell Physiol 283, C895-C904.
51. Gonzalez-Velasquez FJ, Kotarek JA, Moss MA (2008) Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107, 466-477.
52. Gonzalez-Velasquez FJ, Reed JW, Fuseler JW, Matherly EE, Kotarek JA, Soto-Ortega DD, Moss MA (2010) Soluble amyloid-beta protein aggregates induce nuclear factor-kappa B mediated upregulation of adhesion molecule expression to stimulate brain endothelium for monocyte adhesion. J Adhes Sci Technol 24, 2105-2126.
53. Gonzalez-Velasquez FJ, Reed JW, Fuseler JW, Matherly EE, Kotarek JA, Soto-Ortega DD, Moss MA (2011) Activation of brain endothelium by soluble aggregates of the amyloid-beta protein involves nuclear factor-kappa B. Curr Alzheimer Res 8, 81-94.
54. Grammas P, Botchlet T, Fugate R, Ball MJ, Roher AE (1995) Alzheimer disease amyloid proteins inhibit brain endothelial-cell proliferation in vitro. Dementia 6, 126-130.
55. Jahroudi N, Kitney J, Greenberger JS, Bowser R (1998) Endothelial cell dysfunction in response to intracellular overexpression of amyloid precursor protein. J Neurosci Res 54, 828-839.
56. Kania KD,Wijesuriya HC, Hladky SB, Barrand MA (2011) Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells. Brain Res 1418, 1-11.
57. Kusiak JW, Lee LL, Zhao BY (2001) Expression of mutant amyloid precursor proteins decreases adhesion and delays differentiation of Hep-1 cells. Brain Res 896, 146-152.
58. Marco S, Skaper SD (2006) Amyloid beta-peptide(1-42) alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401, 219-224.
59. Nagababu E, Usatyuk PV, Enika D, NatarajanV, Rifkind JM (2009)Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins. J Alzheimers Dis 17, 845-854.
60. Preston JE, Hipkiss AR, Himsworth DTJ, Romero IA, Abbott JN (1998) Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: Protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett 242, 105-108.
61. Simons ER, Marshall DCL, Long HJ, Otto K, Billingslea A, Tibbles H, Wells J, Eisenhauer P, Fine RE, Cribbs DH, Davies TA, Abraham CR (1998) Blood brain barrier endothelial cells express candidate amyloid precursor protein-cleaving secretases. Amyloid 5, 153-162.
62. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P (2000) In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 59, 29-38.
63. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA (2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14, 1101-1112.
64. Xu J, Chen SW, Ku G, Ahmed SH, Xu JM, Chen H, Hsu CY (2001) Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab 21, 702-710.
65. Yang DI, Yeh CH, Chen SW, Xu J, Hsu CY (2004) Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 17, 99-107.
66. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: lrp-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17, 553-570.
67. Merlini M, Meyer EP, Ulmann-Schuler A, Nitsch RM (2011)Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcA beta mice. Acta Neuropathol 122, 293-311.
68. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, Ghiso J, Frangione B, Zlokovic BV (2002) Brain clearance of Alzheimer's amyloid-beta 40 in the squirrel monkey: A SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 10, 359-368.
69. Deane R, Wu ZH, Sagare A, Davis J, Yan SD, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song XM, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of A beta isoforms. Neuron 43, 333-344.
70. Gentile MT, Poulet R, Di Pardo A, Cifelli G, Maffei A, Vecchione C, Passarelli F, Landolfi A, Carullo P, Lembo G (2009) beta Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 30, 222-228.
71. Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, Vogelgesang S (2011) Betaamyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011, 690121.
72. Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, Schumacher T, Bruening T, Plath A-S, Alfen F, Schmidt A, Winter F, Rateitschak K, Wree A, Gsponer J, Walker LC, Pahnke J (2011) Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Investig 121, 3924-3931.
73. Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S,Weggen S, Roebroek AJM, Kuhlmann CRW, Pietrzik CU. (2011) LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 32, 2323.e1-11.
74. Wijesuriya HC, Bullock JY, FaullRLM,Hladky SB, Barrand MA (2010) ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res 1358, 228-238.
75. Pflanzner T, Kuhlmann CR, Pietrzik CU (2010) Bloodbrain-barrier models for the investigation of transporter-and receptor-mediated amyloid-beta clearance in Alzheimer's disease. Curr Alzheimer Res 7, 578-590.
76. Poduslo JF, Curran GL,Wengenack TM, Malester B, Duff K (2001) Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8, 555-567.
77. Bourasset F, Ouellett M, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F (2009) Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 56, 808-813.
78. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470.
79. Vodopivec I, Galichet A, Knobloch M, Bierhaus A, Heizmann CW, Nitsch RM(2009)RAGEdoes not affect amyloid pathology in transgenic ArcA beta mice. Neurodegener Dis 6, 270-280.
80. Wisniewski HM, Vorbrodt AW, Wegiel J (1997) Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease. Ann N Y Acad Sci 826, 161-172.
81. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C,Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
82. Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W (2009) ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta 1-40 peptides. J Neurosci 29, 5463-5475.
83. Bonda DJ,Webber KM, Siedlak SL, Perry G, Friedland RP, Smith MA (2007) The pathology of Alzheimer disease elicits an in vivo immunological response. Am J Immunol 3, 10-14.
84. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2007) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28, 977-986.
85. Bulbarelli A, Lonati E, Brambilla A, Orlando A, Cazzaniga E, Piazza F, Ferrarese C, Masserini M, Sancini G (2012) A beta 42 production in brain capillary endothelial cells after oxygen and glucose deprivation. Mol Cell Neurosci 49, 415-422.
86. Kouznetsova E, Klingner M, Sorger D, Sabri O, Grossmann U, Steinbach J, Scheunemann M, Schliebs R (2006) Developmental and amyloid plaque-related changes in cerebral cortical capillaries in transgenic Tg2576 Alzheimer mice. Int J Dev Neurosci 24, 187-193.
87. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, Duff K, Dickson D, Van Broeckhoven C (2005) Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167, 527-543.
88. Chi XD, Sutton ET, Thomas T, Price JM (1999) The protective effect of K+ channel openers on beta-amyloid induced cerebrovascular endothelial dysfunction. Neurol Res 21, 345-351.
89. Deli MA, Veszelka S, Csiszar B, Toth A, Kittel A, Csete M, Sipos A, Szalai A, Fulop L, Penke B, Abraham CS, Niwa M (2010) Protection of the blood-brain barrier by pentosan against amyloid-beta-induced toxicity. J Alzheimers Dis 22, 777-794.
90. Kook SY, Hong HS, Moon M, Ha CM, Chang S, Mook-Jung I (2012) Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J Neurosci 32, 8845-8854.
91. Carrano A, Hoozemans JJM, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJM (2012) Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 10, 329-331.
92. Humpel C(2008) Basolateral aggregated rat amyloid beta(1-42) potentiates transmigration of primary rat monocytes through a rat blood-brain barrier. Curr Neurovasc Res 5, 185-192.
93. Algotsson A, Winblad B (2007) The integrity of the bloodbrain barrier in Alzheimer's disease. Acta Neurol Scand 115, 403-408.
94. Blennow K, Vanmechelen E (1998) Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transms Suppl 223-235.
95. Jesse S, Brettschneider J, Sussmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC, Tumani H, Otto M(2011) Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol 258, 1034-1041.
96. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, Engelborghs S (2009) No correlation between time-linked plasma and CSF A beta levels. Neurochem Int 55, 820-825.
97. Skoog I,Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, Gottfries CG, Blennow K (1998) A population study on blood-brain barrier function in 85-year-olds-Relation to Alzheimer's disease and vascular dementia. Neurology 50, 966-971.
98. Kassner A, Thornhill R (2011) Measuring the integrity of the human blood-brain barrier using magnetic resonance imaging. Methods Mol Biol 686, 229-245.
99. Armitage PA, Farrall AJ, Carpenter TK, Doubal FN, Wardlaw JM (2011) Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities. Magn Reson Imaging 29, 305-314.
100. Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, Grossetete M, Shah NJ, Wills J, Qualls C, Rosenberg GA (2011) Blood-brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 42, 2158-2163.
101. De Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG (2005) Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 63, 1309-1315.
102. WardlawJM, Doubal F, Armitage P, Chappell F, CarpenterT, Munoz Maniega S, Farrall A, Sudlow C, Dennis M, Dhillon B (2009) Lacunar stroke is associated with diffuse bloodbrain barrier dysfunction. Ann Neurol 65, 194-202.
103. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J (2009) Blood-brain barrier permeability in Alzheimer's disease: A case-control MRI study. Psychiatry Res 171, 232-241.
104. Murugesan N, Demarest TG, Madri JA, Pachter JS. (2012) Brain regional angiogenic potential at the neurovascular unit during normal aging. Neurobiol Aging 33, 1004 e1001-1016.